Michael Dillen

Sound Pharmaceuticals Inc. manufactures biopharmaceutical products. It focuses on developing drug treatments for sensori-neural hearing loss. The company was founded by Eric Lynch, Joseph Ashley, Glenn H. Kawasaki and Jonathan Kil in 2001 and is headquartered in Seattle, WA.

SV Health Investors LLC is a Venture Capital firm, a subsidiary of SV Health Investors LLP founded in 2006. SV Health Investors LLC is headquartered in Boston.

Ethicon, Inc. develops and markets medical products and devices for surgery. It offers different types of services such as wound management, women's health, and cardiovascular surgery. The company was founded by George F. Merson in 1915 and is headquartered in Somerville, NJ.

Tel-Aviv University operates as a university in Israel. Its faculties include arts, engineering, science, humanities, law, life science, management, medicine, and social science. The company was founded in 1956 and is headquartered in Ramat Aviv, Israel.

New York State Bar Association is a non-profit organization, which provides legal services and offers a membership program for lawyers. It also publishes an array of books, bar journals, law digest, and State Bar news. The company was founded in 1876 and is headquartered in Alban, NY.

The District of Columbia Bar provides legal services. The private company is based in Washington.

Part of Santen Pharmaceutical Co., Ltd., Santen, Inc. is a private company that develops ophthalmic products. The company is based in Emeryville, CA. The company was founded in 1993 by Adrienne L. Graves. Tatsuya Kaihara has been the CEO of the company since 2017.

Tel-Aviv Sourasky Medical Center operates as a medical center. Tel Aviv Sourasky Medical Center provides progressive full-service healthcare treatment and research institutions in Israel. The Medical Center draws patients from throughout the world for specialty care and routine procedures through the medical tourism program, designed specifically for the needs of international patients. The center was founded in 1963 and is headquartered in Tel Aviv, Israel.

AlloCure, Inc. develops cell therapies for the treatment of kidney diseases. It engages in developing allogeneic mesenchymal stem cell therapy for acute kidney injury. The company was founded in 2008 and is headquartered in Burlington, MA.

Mimetogen Pharmaceuticals, Inc. develops peptidomimetic small molecule drugs against glaucoma and cancer. Its product mimic the effects of neurotrophin proteins that help to maintain the health and growth of cells and tissues found in the eye. Mimetogen provides tyrosine kinase agonists that prevent neuronal death; small molecule tyrosine kinase receptor agonists, which stimulates mucin secretion from conunctival goblet cells; and small molecule neurotrophin mimetics that rescues retinal pigment epithelial cells from oxidative stress-induced apoptosis. The company was founded by Garth Cumberlidge and H. Uri Saragovi in 2005 and is headquartered in Montreal, Canada.

Carter BloodCare engages in the provision of blood components and transfusion services for North, Central and East Texas. It offers collection, testing, and distribution of blood on a local level. It also provides technical support services and educational programs to employees of area healthcare organizations. The company was founded on January 1, 1998 and is headquartered in Bedford, TX.

Glaucoma Research Foundation provides education services. The non-profit company is based in San Francisco, CA. The company was founded by Adrienne L. Graves. The CEO is Thomas M. Brunner.

Ambos NBGO is a Belgian company that is committed to its clients. The private company's name, which means "both" in Spanish, reflects its focus on the client and the company working together as advisors.

iSTAR Medical SA develops innovative ophthalmic implants. Its products include MINIject, STARflo and STAR Material. The company was founded by Michel Alvarez in 2011 and is headquartered in Wavre, Belgium.

Gadeta BV discovers and develops novel cancer immunotherapies. It provides groundbreaking discoveries regarding the role of cell receptors in the broad of heamatological and solid tumor cells. The firm develops t-cells engineered to express a defined gamma delta, an anti- cancer product that eradicates tumors. The company was founded by Jurgen Kuball in 2015 and is headquartered in Utrecht, Netherlands.

The Foundation of the Society of Retina Specialists provides charity services to education.

Mogrify Ltd. engages in the development of direct cellular conversion technology. It applies its technology to generate internet protocol and cell types that will power the development and manufacture of new cell therapies in any therapeutic area. The company was founded by Julian Gough, Owen John Llewellyn Rackham, and Jose Polo in 2009 and is headquartered in Cambridge, the United Kingdom.

Founded in 2010, Euretina Trading Ltd. is a part of American Society of Retinal Specialists and organizes exhibitions, fairs, and conferences. The private company is based in London, UK.

Part of Notal Vision Ltd., Notal Vision, Inc. develops ophthalmic diagnostic devices. The private company is based in Manassas, VA. The company was founded by Barak Azmon. The CEO is Kester Nahen.

Kintsugi Mindful Wellness Inc. is a company based in Berkeley, CA that is developing a novel voice biomarker infrastructure to detect signs of depression and anxiety from short clips of free form speech. The company's mission is to help close mental healthcare gaps across risk-bearing health systems, to save time and lives. Kintsugi is an end-to-end behavioral health solution developing vocal biomarker technology powered by AI to conduct mental health screenings at scale. The company brings the philosophy of Kintsugi, the art of repairing fractures in ceramics with gold, to strengthening mental wellness infrastructures. The company was founded in 2019 by Rima Seiilova-Olson and Grace Chang. Grace Chang has been the CEO since 2019.

Visus Therapeutics, Inc. is a clinical stage biopharmaceutical company that focuses on developing multi-targeted ophthalmic therapeutics for the front and back of the eye. The company is based in Seattle, WA and has subsidiaries in the United States. The company is developing novel, pupil-modulating therapeutics designed to correct the loss of near vision associated with presbyopia. In parallel, Visus is advancing its pipeline of early-stage ophthalmic drug candidates engineered to preserve and restore visual function associated with the leading causes of vision loss including cataract and presbyopia, ocular surface and corneal disease, glaucoma, and age-related macular degeneration. The company was founded by Benjamin Scot Bergo, Rhett M. Schiffman, and Benjamin Scot Bergo has been the CEO since incorporation.

Invectys, Inc. is a biopharmaceutical company that focuses on developing immunotherapy treatments for cancer. The private company is based in Houston, TX. Invectys was founded in 2010 and Praveen Tyle has been the CEO of the company since 2021.

Tenpoint Therapeutics Ltd. is a British biotechnology company that specializes in developing engineered cell-based therapies and in vivo reprogramming to restore vision for individuals with degenerative ocular diseases. The company is based in Cambridge, UK and was founded in 2020. Tenpoint Therapeutics brings together experts who are shaping the regenerative ocular medicine revolution and the technologies that are driving it. The company's focus is on replacing diseased cells with healthy ones to permanently restore vision. Eddy Anglade has been the CEO of the company since 2023.

Eyebiotech Ltd. develops new generation of therapies for eye diseases. The British company was founded in 2021 by David R. Guyer, Anthony P. Adamis. David R. Guyer has been the CEO since 2021.